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BackgroundᄏSteroid-responsive encephalopathy associated with subacute thyroiditis has, to 
our knowledge, not been reported previously. 
Case ReportᄏA 49-year-old woman was found collapsed and brought to our institution with 
decreased mentality, dysarthria, and gait disturbance. Brain magnetic resonance imaging and 
angiography were normal but blood tests revealed thyroid-autoantibody-negative thyrotoxico-
sis. Results of a 99mtechnetium-pertechnetate scan were compatible with the thyrotoxic phase of 
subacute thyroiditis. 14-3-3 proteins were detected in cerebrospinal fluid. Her mental status 
began to improve from the day following steroid administration. Recurrent encephalopathy 
was found 2 months after the initial admission, which was also effectively treated with steroid. 
ConclusionsᄏWe speculate that steroid-responsive recurrent encephalopathy associated with 
subacute thyroiditis is a subtype of Hashimoto’s encephalopathy, and consider that steroid treat-
ment should not be delayed in suspected patients.  J Clin Neurol 2008;4:167-170
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Introduction 
 
Acute encephalopathy can result from various causes, includ-
ing stroke, seizure, metabolic disturbance, toxic material, and 
infection.
1-4 Hashimoto’s encephalopathy (HE) is also one 
of the causes of treatable encephalopathy. Since the first re-
port of Brain et al.,
1 there have been more than 100 patients 
reported with HE, which has also been termed steroid-res-
ponsive encephalopathy with autoimmune thyroiditis (SR-
EAT) in a recent report.
2,5 HE or SREAT is known to be 
associated with autoimmune thyroid disease (AITD). How-
ever, to our knowledge steroid-responsive encephalopathy 
associated with subacute thyroiditis has never been reported. 
Here we report a case of steroid-responsive recurrent ence-
phalopathy that manifested simultaneously with subacute 
thyroiditis.  
 
Case Report 
 
A 49-year-old woman was brought to our institution due to 
decreased mentality, dysarthria, and gait disturbance. She had 
been found collapsed and confused in her bedroom by her 
daughter. She had experienced an upper respiratory infection 
4 weeks before admission, and had also suffered from hy-
pertension. Her highest level of education was elementary 
school and she was right-handed. On admission her tempera-
ture was 37.6℃ and pulse rate was 93 beat/minute. She had 
mild goiter, of approximately 25 g, and thyroid tenderness. 
The neurologic examination revealed somnolence, memory 
impairment, dysarthria, right-hand weakness, and gait disturb-
ance. The initial impression was acute stroke or seizure. 
However, the results of brain magnetic resonance imaging 
(MRI) including diffusion-weighted imaging and angiogra-
phy were normal. Electroencephalography revealed only in-
termittent generalized delta slowing without epileptiform 
discharges. Her serum levels of total T3, free T4, and thy-
roid-stimulating hormone (TSH) were 392 ng/dL (reference 
range: 80-180 ng/dL), 2.82 ng/dL (reference range: 0.8-1.8 
ng/dL), and <0.01 mU/L (reference range: 0.3-5.0 mU/L), 
respectively. The serum and cerebrospinal fluid (CSF) were 
negative for both antithyroglobulin antibody and antimicro-
somal antibody, and TSH-binding inhibiting immunoglobu-
lin was at 5% (reference range:-10% to 10%). The ery-
throcyte sedimentation rate was 101 mm/h. Thyroid ultrasound  
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revealed a mildly enlarged thyroid and heterogeneous hy-
poechogenicity with a lobulating contour in both thyroids. A 
thyroid scan showed a markedly decreased uptake of 
99mte-
chnetium-pertechnetate (Fig. 1), and fine-needle-aspiration 
cytology revealed multinucleated giant cells in the back-
ground of inflammatory cells (Fig. 2). These findings were 
compatible with the thyrotoxic phase of subacute thyroiditis. 
The CSF examination was normal except for positivity for 
14-3-3 proteins. Venereal Disease Research Labo (VDRL) 
was nonreactive and lupus erythematosus (LE) cells were not 
found. Paraneoplastic antibodies were negative. Antineu-
trophil cytoplasmic antibodies (ANCA), antiphospholipid 
antibody, anticardiolipin antibody, lupus anticoagulant, an-
tinuclear antibody, anti-dsDNA, anti-Sm, anti-RNP, anti-
Ro, anti-La, anti-Scl-70, anti-Jo-1, and anti-SS-Ro52 were 
all within normal limits. Single-photon-emission computed 
tomography demonstrated no perfusion abnormality. 
On the second day of admission, the patient became more 
somnolent and exhibited dysmetria on the right side. She 
was given a nonselective beta-blocker (propranolol), but there 
was no clinical improvement during the following 5 days. The 
score on the Korean Mini Mental Status Examination (K-
MMSE) was 21/30 on the fifth day of admission. On the 
sixth day of admission she was started on oral prednisolone 
(30 mg/day) in addition to the propranolol for 7 days. Her 
mental status began to improve from the next day. Five days 
after beginning steroid treatment, she could walk with assis-
tance, at which time a thyroid function test (TFT) indicated 
that her serum levels of total T3, free T4, and TSH were 128 
ng/dL, 0.93 ng/dL, and <0.01 mU/L, respectively. The gait 
disturbance, dysmetria, and somnolence gradually improved 
thereafter, with the K-MMSE score improving to 25/30. She 
was discharged on an antiepileptic drug. One month later she 
could walk without assistance and showed only mild dysarthria. 
Two months after the initial admission, she felt numbness 
on the right side. It became difficult for her daughter to un-
derstand her speech and she could not walk without assis-
tance. However, there was no clinical or laboratory evidence 
of recurrent viral infection. A repeated TFT demonstrated 
hypothyroidism, with serum total T3 at 42 ng/dL, free T4 at 
0.59 ng/dL, and TSH at 73.9 mU/L. These changes in TFT 
results were attributed to the typical natural course of sub-
acute thyroiditis, and 50 μg of thyroxine replacement was 
initiated and then gradually increased to 100 μg. Four weeks 
later, TFT results showed improvement of hypothyroidism, 
with serum total T3 at 85 ng/dL, free T4 at 0.74 ng/dL, and 
TSH at 43.0 mU/L. However, her symptoms persisted. A 
repeated brain MRI produced normal results. Steroid pulse 
therapy (methylprednisolone, 1 g/day) was given for 3 days, 
after which oral prednisolone was prescribed. She began to 
improve from the next day of steroid pulse therapy. Two 
weeks later, gait disturbance and dysarthria were improved 
and she complained of only mild numbness on the right side.   
 
Discussion 
 
To our knowledge this is the first reported case of steroid-
responsive recurrent encephalopathy associated with sub-
acute thyroiditis, which was diagnosed by thyroid tenderness, 
markedly decreased uptake of 
99mtechnetium-pertechnetate on 
Fig. 1. 
99mTechnetium-pertechnetate scan showing poor visuali-
zation of the thyroid. 
Fig. 2. Fine-needle-aspiration cytology of the thyroid revealing
multinucleated giant cells in the background of inflammatory cells.
The black arrow indicates a multinucleated giant cell (Papanicolaou
staining;  ×400 magnification).  
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the thyroid scan, and thyrotoxicosis followed by hypothy-
roidism on TFT. Encephalopathy was improved with steroid 
treatment. After we excluded vascular, toxic, metabolic, and 
infectious disease, our patient was tentatively diagnosed as 
steroid-responsive recurrent encephalopathy of unknown cause. 
It was very interesting that the clinical manifestations were 
similar to those of HE. However, there was no evidence of 
AITD. 
Various clinical manifestations of HE or SREAT have been 
reported.
2,5-11 Cognitive impairment, high serum concentra-
tions of thyroid autoantibodies, and good responsiveness to 
steroid treatment have been described as common clinical 
features and accepted as diagnostic criteria of HE or SR-
EAT.
1,2,5-9,12,13 However, it is questionable that AITD is 
necessary in the diagnosis of HE or SREAT since there is no 
conclusive evidence that this encephalopathy is caused by 
Hashimoto’s thyroiditis or other autoimmune thyroiditis.
2 
AITD is prevalent in the general population,
6 and there are 
no consistent correlations between the clinical severity and 
the type of thyroid antibody, or the clinical severity and the 
serum concentration of thyroid autoantibodies.
2,5,6,9,12 It has 
been suggested that thyroid autoantibodies are not the cause 
of encephalopathy, but rather simply a marker of some auto-
immunity affecting the brain, such as humoral immunity by 
antineuronal antibody as detected in one patient with HE.
5,11 
Therefore, it appears unreasonable to assume that thyroid 
autoantibodies are required for a diagnosis of HE. The clini-
cal manifestations of our case were similar with those of HE 
except for the absence of thyroid autoantibodies.
2,5,6 Consi-
dering that thyroid autoantibodies have played no pathogenic 
role in patients with HE and that HE is a syndrome entity 
rather than a disease, we tentatively diagnosed our patient as 
HE without AITD. However, tests for the definitive diagno-
sis of HE do not exist, and hence our hypothesis could not be 
verified in this single case. More observations are needed to 
examine this hypothesis. 
Our case showed dramatic neurological improvements 
following steroid treatment, which is one of the typical clini-
cal characteristics of HE.
2,5,6,9-12 Despite considerable debate 
about whether steroid responsiveness can be used in the diag-
nostic criteria of HE,
2,5 a beneficial response to a steroid might 
be the only evidence of autoimmunity
6 or the only feature 
differentiating HE from Creutzfeldt-Jakob disease, especially 
in patients with 14-3-3 proteins in the CSF.
14,15 
The 14-3-3 proteins comprise about 1% of total soluble 
protein in brain
16 and are known to be involved in certain 
neurological disorders such as Creutzfeldt-Jakob disease, HE, 
influenza-associated encephalopathy, and steroid-responsive 
encephalopathy.
7,15-17 Examination of the CSF in our case re-
vealed positivity for 14-3-3 proteins, which suggested that the 
encephalopathy was not associated with a functional disorder, 
but rather with neuronal damage in the brain.
17 Considering 
the responsiveness to steroid treatment, steroid should be 
given as soon as possible to patients with suspected HE since 
delaying treatment might lead to irreversible brain deficits. 
There has been considerable debate about whether thyroid 
dysfunction can cause encephalopathy in patients with 
HE.
5,7,9,11,12 Although there is one report of thyrotoxicosis 
preceding clinical relapse of encephalopathy, antithyroid me-
dication did not improve neurologic deficits and variable 
thyroid functions including hyperthyroidism, hypothyroidism, 
and euthyroidism in patients with HE.
5,7,9 However, to our 
knowledge there has been no report of encephalopathy as-
sociated with both thyrotoxicosis and hypothyroidism.   
Subacute thyroiditis occurred simultaneously with ence-
phalopathy in our case, and the encephalopathy was unlikely 
to have been caused by the thyroid dysfunction induced by 
subacute thyroiditis since the encephalopathy occurred both 
in the thyrotoxic and hypothyroid states. Furthermore, the 
neurologic deficits were not improved for management of 
thyrotoxicosis during the thyrotoxic phase and thyroid hor-
mone replacement during the hypothyroid phase of subacute 
thyroiditis. On the contrary, steroid treatment induced marked 
improvement of neurologic deficits. Our observation was 
compatible with thyroid dysfunction not being the cause of 
neurologic deficits, and hence another mechanism might 
have played a role in the pathogenesis of encephalopathy. A 
common underlying pathomechanism such as common auto-
antibody to thyroid and brain is another possible explanation 
of our case, although we did not detect any abnormal auto-
antibody levels in the patient’s serum.
11 To the best of our 
knowledge, this is the first case report of steroid-responsive 
encephalopathy associated with subacute thyroiditis. 
In conclusion, steroid-responsive encephalopathy associated 
with subacute thyroiditis might be a subtype of HE. Steroid 
treatment should not be delayed in suspected patients since 
the encephalopathy is associated with neuronal damage. 
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